Select Publications:

1. Comparison of the next generation aminoglycoside plazomicin (ACHN-490) to gentamicin, tobramycin, and amikacin. (in press Expert Reviews In Antiinfective Therapy).
2. Zed P, Ensom M, Wilbur K, Kanji S, KoshmanS , Irvine-Meek J, Perreault M, Zelenitsky S. Evaluation of the Canadian Society of Hospital Pharmacists Research Grant Program 1995-2008. Can J Hosp Pharm  2011;64:399-404.
3. Keel R, Zhanel G, Zelenitsky S, Nicolau D. Pharmacodynamic  profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals. Can J Infect Dis Med Microbiol 2011;22:132-6.
4. Zelenitsky S, Alkurdi N, Weber Z, Ariano R, Zhanel G. Preferential emergence of reduced vancomycin susceptibility in healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) during continuous infusion vancomycin therapy (CIV) in an in vitro dynamic model. Antimicrob Agents Chemother. 2011;55(7):3627-30.
5. Zhanel GG, Rossnagel E, Nichol K, Cox L, Karlowsky JA, Zelenitsky S, Noreddin AM, Hoban DJ. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S.aureus and vancomycin-resistant S. aureus using an in vitro model. J Antimicrob Chemother. 2011;66(6):1301-5.
6. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011;37(4):632-8.
7. Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother. 2011;66(2):343-9.
8. Zelenitsky SA, Ariano RE. Support for higher ciprofloxacin AUC24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother. 2010;65:1725-32.
9. Ariano RE, Zelenitsky SA. Should IV antibiotics be administered by prolonged infusion? The "pro" side. CJHP 2010;63:246-248.
10. Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859-86.
11. Ariano RE, Sitar DS, Zelenitsky SA, Zarychanski R, Pisipati A, Ahern S, Kanji S, Rello J, Kumar A. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ. 2010;182(4):357-63.
12. Zhong W, Alfa M, Zelenitsky S, Howie R. Simulation of cyclic reprocessing buildup on reused medical devices. Comput Biol Med. 2009 Jun;39(6):568-77.
13. Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. Ceftaroline: A Novel Broad-Spectrum Cephalosporin with Activity against Meticillin-Resistant Staphylococcus aureus. Drugs. 2009;69(7):809-831.
14. Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009;53(4):1476-1481.
15. Ariano RE, Zelenitsky SA, Kassum DA. Aminoglycoside-induced vestibular injury: maintaining a sense of balance. Ann Pharmacother. 2008;42(9):1282-1289.
16. Takla TA, Zelenitsky SA, Vercaigne LM. Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections. J Antimicrob Chemother. 2008;62(5):1024-1026.
17. Maharaj AR, Zelenitsky SA, Vercaigne LM. Effect of an ethanol/trisodium citrate hemodialysis catheter locking solution on isolates of Candida albicans. Hemodial Int. 2008;12(3):342-7.
18. Takla TA, Zelenitsky SA, Vercaigne LM. Effect of ethanol/trisodium citrate lock on microorganisms causing hemodialysis catheter-related infections. J Vasc Access 2007;8(4):262-267.

Return to Faculty of Pharmacy Staff Page

Last updated: Jan 2012